Short Interest in enGene Holdings Inc. (NASDAQ:ENGNW) Grows By 250.0%

enGene Holdings Inc. (NASDAQ:ENGNW) was the recipient of a large growth in short interest in the month of July. As of July 31st, there was short interest totalling 2,800 shares, a growth of 250.0% from the July 15th total of 800 shares. Based on an average daily trading volume, of 6,500 shares, the days-to-cover ratio is currently 0.4 days.

enGene Stock Performance

NASDAQ ENGNW traded up $0.14 on Monday, reaching $0.96. The company’s stock had a trading volume of 1,400 shares, compared to its average volume of 23,735. enGene has a 52 week low of $0.39 and a 52 week high of $6.50. The business has a 50-day moving average price of $1.33 and a 200 day moving average price of $2.87.

About enGene

enGene Holdings Inc, through its subsidiary enGene, Inc, operates as a clinical-stage biotechnology company that develops genetic medicines through the delivery of therapeutics to mucosal tissues and other organs. Its lead product candidate is EG-70 (detalimogene voraplasmid), which is a non-viral immunotherapy to treat non-muscle invasive bladder cancer patients with carcinoma-in-situ (Cis), who are unresponsive to treatment with Bacillus Calmette-Guérin.